ACTU
Actuate Therapeutics Inc
Biotechnology
Market Cap$48M
5Y Perf.-74.9%
Build Your Comparison
Side-by-side financial analysisACTU
IDYA
IMVT
TPVG
Try popular comparisons:
Stock Comparison
ACTU vs IDYA vs IMVT vs TPVG
Revenue, margins, valuation, and 5-year total return — side by side.
IDYA
IDEAYA Biosciences, Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-26.6%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.+8.8%
TPVG
TriplePoint Venture Growth BDC Corp.
Asset Management
Market Cap$226M
5Y Perf.-26.0%
ACTU vs IDYA vs IMVT vs TPVG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ACTU |  IDYA |  IMVT |  TPVG |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Asset Management |
| Market Cap | $48M | $2.55B | $6.90B | $226M |
| Revenue (TTM) | $0.00 | $225M | $0.00 | $61M |
| Net Income (TTM) | $-22M | $-140M | $-506M | $-12M |
| Gross Margin | — | 99.5% | — | 72.9% |
| Operating Margin | — | -81.4% | — | -35.9% |
| Forward P/E | — | — | — | 6.0x |
| Total Debt | $405K | $28M | $72K | $469M |
| Cash & Equiv. | $13M | $113M | $902M | $20M |
ACTU vs IDYA vs IMVT vs TPVG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACTU
IDYA
IMVT
TPVG
| Stock | Aug 24 | Jun 26 | Return |
|---|---|---|---|
| Actuate Therapeutic… (ACTU) | 100 | 25.1 | -74.9% |
| IDEAYA Biosciences,… (IDYA) | 100 | 73.4 | -26.6% |
| Immunovant, Inc. (IMVT) | 100 | 108.8 | +8.8% |
| TriplePoint Venture… (TPVG) | 100 | 74.0 | -26.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACTU vs IDYA vs IMVT vs TPVG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TPVG leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. IDYA also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇TPVG emerged as the overall leader. Track its performance:
ACTU
Actuate Therapeutics Inc
The Secondary Option
ACTU lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
IDYA
IDEAYA Biosciences, Inc.
The Growth Play
IDYA is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 30.2%, EPS growth 61.9%, 3Y rev CAGR 62.5%
- Lower volatility, beta 1.25, Low D/E 2.7%, current ratio 11.34x
- Beta 1.25, current ratio 11.34x
- 30.2% revenue growth vs IMVT's -22.2%
Best for: growth exposure and sleep-well-at-night
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 237.9% 10Y total return vs IDYA's 159.0%
- 2.6% margin vs IDYA's -62.2%
- +110.9% vs ACTU's -76.5%
Best for: long-term compounding
TPVG
TriplePoint Venture Growth BDC Corp.
The Banking Pick
TPVG carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 0.65, yield 18.4%
- Beta 0.65 vs ACTU's 2.21
- 18.4% yield; the other 3 pay no meaningful dividend
- -1.5% ROA vs ACTU's -180.9%
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  IDYA | 30.2% revenue growth vs IMVT's -22.2% |
| Quality / Margins |  IMVT | 2.6% margin vs IDYA's -62.2% |
| Stability / Safety |  TPVG | Beta 0.65 vs ACTU's 2.21 |
| Dividends | TPVG | 18.4% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | IMVT | +110.9% vs ACTU's -76.5% |
| Efficiency (ROA) | TPVG | -1.5% ROA vs ACTU's -180.9% |
ACTU vs IDYA vs IMVT vs TPVG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
Segment breakdown not available.
ACTU vs IDYA vs IMVT vs TPVG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTPVGLAGGINGIDYA
Who Leads Where
TPVG leads in 2 of 6 categories
IMVT leads 1 • ACTU leads 0 • IDYA leads 0 • 2 tied
Explore the data ↓IDYAIDEAYA Biosciences, I…
0leads
ACTUActuate Therapeutics …
0leads
IMVTImmunovant, Inc.
1leads
TPVGTriplePoint Venture G…
2leads
6 Total Categories
CATEGORYLEADERvs IMVTvs ACTUMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
TPVG2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TPVG6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — IDYA and TPVG each lead in 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
IDYA and IMVT operate at a comparable scale, with $225M and $0 in trailing revenue. TPVG is the more profitable business, keeping -19.5% of every revenue dollar as net income compared to IDYA's -62.2%.
| Metric |  ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $225M | $0 | $61M |
| EBITDAEarnings before interest/tax | -$22M | -$179M | -$532M | -$22M |
| Net IncomeAfter-tax profit | -$22M | -$140M | -$506M | -$12M |
| Free Cash FlowCash after capex | -$20M | -$88M | -$407M | -$59M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% | — | +72.9% |
| Operating MarginEBIT ÷ Revenue | — | -81.4% | — | -35.9% |
| Net MarginNet income ÷ Revenue | — | -62.2% | — | -19.5% |
| FCF MarginFCF ÷ Revenue | — | -39.0% | — | -97.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | -35.4% | -14.1% | -2.3% |
Evenly matched — IDYA and TPVG each lead in 2 of 5 comparable metrics.
Valuation Metrics
TPVG leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| Market CapShares × price | $48M | $2.5B | $6.9B | $226M |
| Enterprise ValueMkt cap + debt − cash | $36M | $2.5B | $6.0B | $675M |
| Trailing P/EPrice ÷ TTM EPS | -1.91x | -22.64x | -12.14x | 4.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 5.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 4.50x |
| EV / EBITDAEnterprise value multiple | — | — | — | 8.91x |
| Price / SalesMarket cap ÷ Revenue | — | 11.64x | — | 2.33x |
| Price / BookPrice ÷ Book value/share | 5.36x | 2.51x | 7.19x | 0.63x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
TPVG leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TPVG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TPVG delivers a -3.4% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-4 for ACTU. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to TPVG's 1.33x. On the Piotroski fundamental quality scale (0–9), ACTU scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.3% | -14.0% | -68.2% | -3.4% |
| ROA (TTM)Return on assets | -180.9% | -12.8% | -62.2% | -1.5% |
| ROICReturn on invested capital | — | -12.4% | — | +7.2% |
| ROCEReturn on capital employed | -5.1% | -15.0% | -68.3% | +9.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.05x | 0.03x | 0.00x | 1.33x |
| Net DebtTotal debt minus cash | -$13M | -$85M | -$902M | $449M |
| Cash & Equiv.Liquid assets | $13M | $113M | $902M | $20M |
| Total DebtShort + long-term debt | $404,991 | $28M | $72,000 | $469M |
| Interest CoverageEBIT ÷ Interest expense | -1073.65x | — | — | -1.02x |
TPVG leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $2,346 for ACTU. Over the past 12 months, IMVT leads with a +110.9% total return vs ACTU's -76.5%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs ACTU's -38.3% — a key indicator of consistent wealth creation.
| Metric | ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -66.5% | -14.4% | +29.8% | -12.7% |
| 1-Year ReturnPast 12 months | -76.5% | +30.1% | +110.9% | -10.7% |
| 3-Year ReturnCumulative with dividends | -76.5% | +15.0% | +55.0% | -22.4% |
| 5-Year ReturnCumulative with dividends | -76.5% | +31.8% | +213.0% | -23.3% |
| 10-Year ReturnCumulative with dividends | -76.5% | +159.0% | +237.9% | +85.3% |
| CAGR (3Y)Annualised 3-year return | -38.3% | +4.8% | +15.7% | -8.1% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and TPVG each lead in 1 of 2 comparable metrics.
Risk & Volatility
TPVG is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than ACTU's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.7% from its 52-week high vs ACTU's 21.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.21x | 1.25x | 1.66x | 0.65x |
| 52-Week HighHighest price in past year | $9.25 | $39.28 | $36.27 | $7.50 |
| 52-Week LowLowest price in past year | $1.60 | $20.50 | $14.32 | $4.48 |
| % of 52W HighCurrent price vs 52-week peak | +21.8% | +73.8% | +92.7% | +74.3% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 48.8 | 57.9 | 49.9 |
| Avg Volume (50D)Average daily shares traded | 178K | 1.3M | 1.9M | 298K |
Evenly matched — IMVT and TPVG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ACTU as "Buy", IDYA as "Buy", IMVT as "Buy", TPVG as "Hold". Consensus price targets imply 939.6% upside for ACTU (target: $21) vs 29.9% for IMVT (target: $44). TPVG is the only dividend payer here at 18.40% yield — a key consideration for income-focused portfolios.
| Metric | ACTUActuate Therapeut… | IDYAIDEAYA Bioscience… | IMVTImmunovant, Inc. | TPVGTriplePoint Ventu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $21.00 | $58.67 | $43.67 | $8.95 |
| # AnalystsCovering analysts | 1 | 25 | 23 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +18.4% |
| Dividend StreakConsecutive years of raises | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $1.02 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TPVG leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). IMVT leads in 1 (Total Returns). 2 tied.
Best OverallTriplePoint Venture Growth … (TPVG)Leads 2 of 6 categories
Loading custom metrics...
ACTU vs IDYA vs IMVT vs TPVG: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ACTU or IDYA or IMVT or TPVG a better buy right now?
For growth investors, IDEAYA Biosciences, Inc.
(IDYA) is the stronger pick with 30. 2% revenue growth year-over-year, versus 36. 6% for TriplePoint Venture Growth BDC Corp. (TPVG). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 6x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Actuate Therapeutics Inc (ACTU) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACTU or IDYA or IMVT or TPVG?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -76. 5% for Actuate Therapeutics Inc (ACTU). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus ACTU's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACTU or IDYA or IMVT or TPVG?
By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.
(TPVG) is the lower-risk stock at 0. 65β versus Actuate Therapeutics Inc's 2. 21β — meaning ACTU is approximately 242% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — ACTU or IDYA or IMVT or TPVG?
By revenue growth (latest reported year), IDEAYA Biosciences, Inc.
(IDYA) is pulling ahead at 30. 2% versus 36. 6% for TriplePoint Venture Growth BDC Corp. (TPVG). On earnings-per-share growth, the picture is similar: Actuate Therapeutics Inc grew EPS 67. 5% year-over-year, compared to -1. 5% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACTU or IDYA or IMVT or TPVG?
TriplePoint Venture Growth BDC Corp.
(TPVG) is the more profitable company, earning 50. 6% net margin versus -52. 0% for IDEAYA Biosciences, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -72. 8% for IDYA. At the gross margin level — before operating expenses — IDYA leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ACTU or IDYA or IMVT or TPVG more undervalued right now?
Analyst consensus price targets imply the most upside for ACTU: 939.
6% to $21. 00.
07Which pays a better dividend — ACTU or IDYA or IMVT or TPVG?
In this comparison, TPVG (18.
4% yield) pays a dividend. ACTU, IDYA, IMVT do not pay a meaningful dividend and should not be held primarily for income.
08Is ACTU or IDYA or IMVT or TPVG better for a retirement portfolio?
For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.
(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), 18. 4% yield). Actuate Therapeutics Inc (ACTU) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +85. 3%, ACTU: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ACTU and IDYA and IMVT and TPVG?
These companies operate in different sectors (ACTU (Healthcare) and IDYA (Healthcare) and IMVT (Healthcare) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACTU is a small-cap quality compounder stock; IDYA is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while ACTU, IDYA, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.